Stockscreener 앱 받기
17.00
1.39%
-0.24
시간 외 거래:
16.80
-0.20
-1.18%
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug - TradingView
Viridian therapeutics enters commercial manufacturing agreement with Wuxi biologics on May 24, 2026 - marketscreener.com
Viridian (VRDN) secures WuXi Biologics pact for long-term veligrotug manufacturing - Stock Titan
Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)? - Sahm
Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings - MSN
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - Insider Monkey
Viridian Therapeutics releases topline phase 3 TED data elegrobart - Eyes On Eyecare
VRDN Stock Price, Quote & Chart | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - ChartMill
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - AOL.com
Viridian Therapeutics launches $250M concurrent debt and equity offerings - MSN
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026News and Statistics - IndexBox
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - The Motley Fool
Why is Viridian Therapeutics stock sinking Monday? - MSN
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Liquidity Mapping Around (VRDN) Price Events - Stock Traders Daily
VRDN Maintained by Evercore ISI Group -- Price Target Lowered to $26 - GuruFocus
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN - Benzinga
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History - Benzinga
Bellevue Group (VRDN) files Schedule 13G for 6.6% ownership - Stock Titan
Viridian Therapeutics stock (US92769V1044): Q1 earnings beat and Phase 3 data boost - AD HOC NEWS
Fairmount Healthcare Fund II invests $20m in Viridian Therapeutics By Investing.com - Investing.com Australia
Viridian Therapeutics(VRDN.US) 10% Shareholder Buys US$20 Million in Common Stock - Moomoo
Fairmount-linked fund boosts Viridian (VRDN) stake with 1.18M-share open-market buy - Stock Titan
Fairmount boosts Viridian Therapeutics (VRDN) stake to 14.04% after $20M share purchase - Stock Titan
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
How Strong REVEAL-2 Data and Fresh Capital Raises Could Shape Viridian Therapeutics (VRDN) Investors - Sahm
VRDN6389238 Bond Coupon Analysis — Rate & Payments - TradingView
VRDN6389238 Bond Analysis — Key Metrics - TradingView
Viridian Therapeutics stock (US92769V1044): Q1 beat with 95.8% revenue surge - AD HOC NEWS
Viridian Therapeutics, Inc. Bonds — Corporate Bond Rates - TradingView
Viridian Therapeutics Raises $359 Million in Offerings - TipRanks
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event - Stock Titan
VRDN6389238 Bond Price and Chart — FINRA:VRDN6389238 - TradingView
Number of shareholders of Viridian Therapeutics, Inc. – NASDAQ:VRDN - TradingView
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha
Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings - Sahm
Deep Track files 5.30% stake in Viridian Therapeutics (NYSE: VRDN) as Schedule 13G - Stock Titan
Viridian Therapeutics (NASDAQ: VRDN) offers $225M convertibles; concurrent equity deal - Stock Titan
Viridian Therapeutics (VRDN) files 7.35M-share sale, concurrent $225M notes - Stock Titan
Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising - Yahoo Finance
Viridian Therapeutics | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses - Moomoo
Viridian prices $225M convertible notes, $125M equity offering - Investing.com UK
MSN Money - MSN
Viridian Therapeutics (VRDN) Announces $350M Public Offerings fo - GuruFocus
Viridian Therapeutics Plans to Use Proceeds to Repay Debt, Fund Studies for Thyroid Eye Disease Franchise, Advance R&D >VRDN - Moomoo
Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Viridian Therapeutics Prices Upsized Public Offering of 7.35M Shares at $17 Each >VRDN - Moomoo
0.98%
0.12%
자본화:
|
볼륨(24시간):